Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort

Overview of attention for article published in Cancer Immunology Research, September 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#11 of 1,611)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 25 news outlets
blogs: 2 blogs
twitter: 13 X users

facebook: 2 Facebook pages
googleplus: 1 Google+ user

Citations

dimensions_citation: 68 Dimensions

Readers on

mendeley: 58 Mendeley

Summary News Blogs X Facebook Google+ Dimensions citations

So far, Altmetric has seen 2 public wall posts from 2 users.

Labome News, 16 Jul 2018

[early] Immunotherapy with checkpoint inhibitors doubles survival rates for patients with melanoma brain metastases. http://bit.l…

Fighting Melanoma, 13 Jul 2018

The successes of checkpoint blockade immunotherapy (CBI) and BRAFV600-targeted therapy trials have generated substantial…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.